Literature DB >> 16305061

Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome.

Timo Saaristo1, Markku Peltonen, Jaana Lindström, Liisa Saarikoski, Jouko Sundvall, Johan Gunnar Eriksson, Jaakko Tuomilehto.   

Abstract

The aim of this study was to assess the performance of the Finnish Diabetes Risk Score as a screening tool for undetected type 2 diabetes (T2D), abnormal glucose tolerance (AGT) and metabolic syndrome in the general population. In a cross-sectional, population-based survey, a total of 4,622 subjects aged 45-74 years were invited to a health examination that included an oral glucose tolerance test. Full data with risk score estimate and glucose tolerance status were available for 2,966 subjects without a prior history of diabetes. The risk score was associated with the presence of previously undiagnosed T2D, AGT, metabolic syndrome and cardiovascular risk factors. The area under the receiver operating curve for the prevalence of undiagnosed diabetes was 0.72 in men and 0.73 in women. The sensitivity using a cutoff risk score of 11 to identify undiagnosed diabetes was 66% in men and 70% in women; the corresponding false-positive rates were 31% and 39%, respectively. The area under the receiver operating curve for detecting the metabolic syndrome was 0.72 in men and 0.75 in women. The Finnish Diabetes Risk Score can be used as a self-administered test to screen subjects at high risk for T2D. It can also be used in the general population and clinical practice to identify undetected T2D, AGT and the metabolic syndrome.

Entities:  

Mesh:

Year:  2005        PMID: 16305061     DOI: 10.3132/dvdr.2005.011

Source DB:  PubMed          Journal:  Diab Vasc Dis Res        ISSN: 1479-1641            Impact factor:   3.291


  82 in total

Review 1.  A clinical prescription for heart health in midlife women.

Authors:  Chrisandra Shufelt; Erika Dutra; Tina Torbati; Tina Ramineni
Journal:  Maturitas       Date:  2018-11-12       Impact factor: 4.342

Review 2.  Treating to protect: current cardiovascular treatment approaches and remaining needs.

Authors:  Michael Böhm; Christian Werner; Anne Jakobsen; Jose Heroys; Ann Ralph; Tomas Rees; Michael Shaw
Journal:  Medscape J Med       Date:  2008-03-26

3.  Screening score for early detection of cardio-metabolic risk in Indian adults.

Authors:  Deepa Pandit-Agrawal; Anuradha Khadilkar; Shashi Chiplonkar; Vaman Khadilkar; Vivek Patwardhan
Journal:  Int J Public Health       Date:  2017-06-21       Impact factor: 3.380

4.  Evaluation of the Finnish Diabetes Risk Score (FINDRISC) as a screening tool for the metabolic syndrome.

Authors:  Mohsen Janghorbani; Hoseinali Adineh; Masoud Amini
Journal:  Rev Diabet Stud       Date:  2014-02-10

5.  How can we identify candidates at highest risk--to screen or not to screen?

Authors:  N C Barengo; J O Tuomilehto
Journal:  Herz       Date:  2016-05       Impact factor: 1.443

6.  A Self-assessment Tool for Screening Young Adults at Risk of Type 2 Diabetes Using Strong Heart Family Study Data.

Authors:  Fengxia Yan; EunSeok Cha; Elisa T Lee; Robert M Mayberry; Wenyu Wang; Guillermo Umpierrez
Journal:  Diabetes Educ       Date:  2016-07-31       Impact factor: 2.140

7.  Performance of Indian Diabetes Risk Score (IDRS) as screening tool for diabetes in an urban slum.

Authors:  Puja Dudeja; Gurpreet Singh; Tukaram Gadekar; Sandip Mukherji
Journal:  Med J Armed Forces India       Date:  2016-10-18

8.  Risk factors for type 2 diabetes among female Pakistani immigrants: the InvaDiab-DEPLAN study on Pakistani immigrant women living in Oslo, Norway.

Authors:  Victoria Telle Hjellset; Benedikte Bjørge; Hege R Eriksen; Arne T Høstmark
Journal:  J Immigr Minor Health       Date:  2011-02

9.  Type 2 Diabetes Genetics: Beyond GWAS.

Authors:  Dharambir K Sanghera; Piers R Blackett
Journal:  J Diabetes Metab       Date:  2012-06-23

Review 10.  How should the clinician most effectively prevent type 2 diabetes in the obese person at high risk?

Authors:  Peter E H Schwarz; Jiang Li; Jaana Lindström; Antje Bergmann; Ulrike Gruhl; Timo Saaristo; Jaakko Tuomilehto
Journal:  Curr Diab Rep       Date:  2007-10       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.